Jovanovic L, Delahunt B, McIver B, Eberhardt N L, Grebe S K G
Department of Pathology and Molecular Medicine, University of Otago, School of Medicine and Health Sciences, Wellington, New Zealand.
J Pathol. 2008 Jun;215(2):145-54. doi: 10.1002/path.2342.
Papillary thyroid carcinoma (PTC) is frequently multifocal (mPTC), with synchronous tumour foci often showing varied morphology. The genetic mechanisms underlying the development of multiple and histologically diverse tumour foci remain uncertain. Different tumour foci might develop either through intrathyroidal dissemination of a single malignant clone, with morphotype differentiation occurring as a result of subclonal progression, or they may stem from independent transformational events involving multiple progenitor clones. To determine the clonal derivation of multiple tumour foci and to map their clonal relationships and genetic progression in mPTC, we evaluated genome-wide allelic imbalances (AI) and BRAF V600E mutation status in 55 synchronous tumour foci from 18 mPTC patients. For apparently monoclonal tumours, we calculated the probabilities of monoclonal derivation and used phylogenetic analysis to model clonal evolution. Genome-wide allelotyping and BRAF mutation analysis showed genetic alterations consistent with monoclonal origin in 83% of cases, mostly with evidence of subclonal evolution. BRAF V600E mutations were early events during clonal evolution of most, but not all cases. MPTC with morphologically diverse tumour foci also arose through monoclonal derivation in 75% of cases, demonstrating that morphotype-determining genetic changes can be acquired during clonal diversification, subsequent to the spread of the original malignant progenitor clone. In 17% of patients, discordant AI or BRAF V600E profiles implied that mPTCs can occasionally develop from distinct transformation events. This study suggests that mPTC originates usually from neoplastic transformation and subsequent intrathyroidal spread of a single malignant progenitor clone. Clonal progression and morphotype differentiation occur through progressive acquisition of genetic alterations subsequent to the initial intra-glandular spread. In monoclonal BRAF V600E-positive mPTCs, BRAF V600E is not always present in all tumour foci, indicating that other tumour-genetic factors in the primary progenitor clone can also trigger PTC neoplastic transformation.
甲状腺乳头状癌(PTC)常为多灶性(mPTC),同步性肿瘤病灶常呈现不同形态。多个组织学上不同的肿瘤病灶发生发展的遗传机制仍不明确。不同肿瘤病灶可能通过单个恶性克隆在甲状腺内播散形成,形态型分化是亚克隆进展的结果,或者它们可能源于涉及多个祖细胞克隆的独立转化事件。为了确定多灶性肿瘤病灶的克隆起源,并描绘其在mPTC中的克隆关系和遗传进展,我们评估了18例mPTC患者55个同步性肿瘤病灶的全基因组等位基因失衡(AI)和BRAF V600E突变状态。对于明显为单克隆性的肿瘤,我们计算了单克隆起源的概率,并使用系统发育分析来模拟克隆进化。全基因组等位基因分型和BRAF突变分析显示,83%的病例存在与单克隆起源一致的基因改变,大多有亚克隆进化的证据。BRAF V600E突变是大多数(但并非所有)病例克隆进化过程中的早期事件。75%形态学上不同肿瘤病灶的mPTC也通过单克隆起源形成,这表明形态型决定基因改变可在原始恶性祖细胞克隆播散后的克隆多样化过程中获得。17%的患者中,不一致的AI或BRAF V600E图谱提示mPTC偶尔可源于不同的转化事件。本研究表明,mPTC通常起源于单个恶性祖细胞克隆的肿瘤转化及随后的甲状腺内播散。克隆进展和形态型分化通过腺体内初始播散后逐渐获得基因改变而发生。在单克隆BRAF V600E阳性的mPTC中,BRAF V600E并非总是存在于所有肿瘤病灶中,这表明原始祖细胞克隆中的其他肿瘤遗传因素也可触发PTC肿瘤转化。